Opis działalności
Medigene AG is a publicly listed (Frankfurt: MDG1, prime standard) biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative, complementary treatment platforms to target various types and stages of cancer with candidates in clinical and pre-clinical development. Medigene concentrates on the development of personalized T cell-based immunotherapies.
Zarząd & Rada nadzorcza
| CEO |
| Prof. Dr. Dolores J. Schendel |
| Zarząd |
| Axel-Sven Malkomes |
| Rada nadzorcza |
| Dr. Gerd Zettlmeissl, Antoinette Hiebeler-Hasner, Dr. Anthony Man, Dr. Frank Mathias, Dr. Keith Manchester, Ronald Scott |
Dane firmy
| Nazwa: |
Medigene AG |
| Adres: |
Lochhamer Str. 11,D-82152 Planegg/Martinsried |
| Telefon: |
+49-89-200033-0 |
| Fax: |
+49-89-200033-2920 |
| E-mail: |
medigene@medigene.com
|
| Internet: |
www.medigene.com |
| Przemysł: |
Biotechnologia |
| Sektor: |
Biotechnologia |
| Podsektor: |
Biotechnologia |
| Koniec roku finansowego: |
31.12 |
| Free float: |
85,50% |
| Data IPO: |
30.06.2000 |
Relacje inwestorskie
| Nazwa: |
Dr. Anna Niedl |
| Telefon: |
+49-89-200033-3301 |
| Fax: |
- |
| E-mail: |
investor@medigene.com
|
